This page is updated frequently with new G Protein-related patent applications.
| Device for detecting misfolded proteins and methods of use thereof|
The present invention relates to diagnostic devices as well as methods of using these devices for detecting proteins of interest associated with diseases or disorders in mammals. In particular, the proteins of interest may be misfolded proteins associated with certain misfolded-protein disorders in mammals including those mammals suspected of or at risk of having such disorders..
| Protein labeling with cyanobenzothiazole conjugates|
The invention provides compounds and methods for site-specifically labeling proteins with cyanobenzothiazole derivatives of formula i. For example, the invention provides methods for labeling the n-terminus of a protein that terminates with a cysteine residue.
| Novel dna-binding proteins and uses thereof|
Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel dna-binding domains, including tale dna-binding domains. Also disclosed are methods of using these novel dna-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences..
Sangamo Biosciences, Inc.
| Methods and products for expressing proteins in cells|
The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the dna sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic rna molecules.
Factor Bioscience Inc.
| Human antigen binding proteins that bind betta-klotho, fgf receptors and complexes thereof|
The present invention provides compositions and methods relating to or derived from antigen binding proteins activate fgf21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-klotho; (ii) fgfr1c, fgfr2c, fgfr3c or fgfr4; or (iii) a complex comprising β-klotho and one of fgfr1c, fgfr2c, fgfr3c, and fgfr4.
| Cd86 antagonist multi-target binding proteins|
This disclosure provides a multi-specific fusion protein composed of a cd86 antagonist binding domain and another binding domain that is an il-10 agonist, an hla-g agonist, an hgf agonist, an il-35 agonist, a pd-1 agonist, a btla agonist, a light antagonist, a gitrl antagonist or a cd40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains.
Aptevo Research And Development Llc
| Binding proteins against vegf, pdgf, and/or their receptors|
Binding proteins that bind one or more of vegf, pdgf and/or their receptors, including antibodies, cdr-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins..
| Compositions and methods for treating and preventing staphylococcus aureus infections|
Antibodies having fab regions that specifically bind to staphylococcus aureus protein a are capable of mediating opsinization of staphylococcus aureus bacteria despite their expression of antibody-neutralizing protein a. These antibodies and antigen-binding fragments thereof can be used in methods of treating and/or preventing staphylococcus aureus infections..
| Factor viii fusion protein|
The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated factor viii molecules fused to a polypeptide such as e.g.
Novo Nordisk A/s
| Targeted therapeutics|
The present invention relates to compositions, methods and kits for delivery of active agents (x) to cells or tissues that express proteoglycans. More specifically, the present invention relates to conjugates comprising (hb-linker)n-xm-(linker-hb)o, where hb is a heparin binding protein, x is an active agent such as a therapeutic protein (including a functional fragment or variant thereof), or a therapeutic small molecule, linker is a linker entity and m is an integer of at least 1, and n+o is an integer of at least 1.
The Brigham And Women's Hospital, Inc.
Long acting proteins and peptides and methods of making and using the same
Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer ifn-γ conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to ifn-γ, particularly via a free cysteine in the protein.
Bolder Biotechnology, Inc.
Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
The present invention relates to compositions and methods for preparing splice variants of tnfalpha receptor (tnfr) in vivo or in vitro, and the resulting tnfr protein variants. Such variants may be prepared by controlling the splicing of pre-mrna molecules and regulating protein expression with splice switching oligonucleotides or splice switching oligomers (ssos).
Roche Innovation Center Copenhagen A/s
Compositions and methods of preparing leptospira
The present invention includes compositions and methods of preparing flagellar-coiling protein 1 (fcp1)-deficient leptospira bacterium. In one aspect, the invention includes an isolated, flagellar-coiling protein 1 (fcp1)-deficient leptospira bacterium.
Igfbp7 for diagnosing diastolic dysfunction
The present invention relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method comprises measuring the level of igfbp7 (insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level.
Roche Diagnostics Operations, Inc.
Method for detecting protein-protein interaction
Determining an interaction between the first protein and the second protein according to the detection of the fluorescent focus.. .
Ager-peptides and use thereof
The present invention relates to the identification, functionality and use of domains from the n terminus of the receptor for advanced glycation end products (ager). These domains, called receptor mulitimerization epitope (rme), are highly conserved in all ager protein sequences.
Abbvie Deutschland Gmbh & Co. Kg
Oncostatin m receptor antigen binding proteins
The invention provides anti-oncostatin m receptor-β (osmr) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. Osmr antigen binding proteins interfere with binding of osm and/or il-31 to osmr.
Kiniksa Pharmaceuticals, Ltd.
Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
The present invention provides compositions and methods which involve specifically antagonizing gdf8 and activin a. In certain embodiments, compositions are provided which comprise a gdf8-specific binding protein and an activin a-specific binding protein.
Regeneron Pharmaceuticals, Inc.
Fusion proteins comprising igg2 hinge domains
The present invention relates to biologically active fusion proteins containing the igg2 hinge as a multimerization domain capable of multimerizing proteins, peptides and small molecules which are active or more active in multimeric form; compositions comprising such fusion proteins; and methods of making and using such fusion proteins.. .
Uses of diazepane derivatives
The present invention provides compounds of formula (ii) (e.g., compounds of formula (i)), and pharmaceutically compositions thereof. Compounds of formula (ii) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.
Methods and compositions for the stabilization of proteins
The present disclosure relates to buffer-stabilized protein compositions and methods of making the same. The disclosed compositions and methods provide a means of stabilizing and preserving proteins or peptides in such a way that the proteins or peptides maintain their native conformation and structure, maintain biological activity, and prevent aggregation..
Multivalent stable vaccine composition and methods of making same
Stable immunogenic composition capable of eliciting a robust and durable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising at least one antigen consisting of a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores. Method making and using a stable immunogenic composition capable of eliciting a stable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising providing an immunogenic composition comprising at least one antigen comprising a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores and administering the immunogenic composition to an individual..
Compositions and methods to promote wound healing
Compositions and methods to promote wound healing are described. The compositions and methods up-regulate x-box binding protein 1 (xbp1) and/or inositol-requiring enzyme-1 (ire-1).
Wayne State University
Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur-containing, amino acid-specific small molecules
The present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of cellular metabolic anomalies or other undesirable physiological conditions, including cancer, where the normal cellular biochemical function and/or the expression levels of various proteins/enzymes (i.e., the target molecules) are abnormal and must be modified and/or modulated in order to treat these metabolic anomalies or other undesirable physiological conditions, including cancer. The aforementioned target molecules, by way of non-limiting example, include: anaplastic lymphoma kinase (alk), mesenchymal epithelial transition (met) kinase, the receptor tyrosine kinase (ros1), epidermal growth factor receptor (egfr), peroxiredoxin (prx), excision repair cross-complementing protein 1 (ercc1), insulin growth factor 1 receptor (igf1r), ribonucleotide reductase (rnr), tubulin, farnesyltransferase, and various other classes of proteins/enzymes.
Bionumerik Pharmaceuticals, Inc.
Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
The invention relates to biomarkers associated with diabetes, including protein and lipid metabolite biomarkers, methods of using the biomarkers to determine the risk that an individual will develop diabetes, and methods of screening a population to identify persons at risk for developing diabetes and other pre-diabetic conditions.. .
True Health Diagnostics, Llc
Method to identify compounds able to bind to the rossmann fold of c-terminal-binding proteins, identified compounds and medical uses thereof
The invention refers to a method for identifying an anti-tumoral and/or anti-proliferative and/or an inhibitor of the fission machinery involved in mitotic golgi partitioning and/or a molecule modulator of ctbp corepressor activity by testing their affinity binding for the rossmann fold of c-terminal-binding proteins (ctbps); to said identified molecules and to the use thereof as anti-proliferative and/or anti tumoral agents.. .
Consiglio Nazionale Delle Ricerche
Inhibitors of thioredoxin-interacting protein (txnip) for therapy
Described is a compound capable of reducing or inhibiting (a) the biological activity of thioredoxin-interacting protein (txnip) or (b) the expression of the gene encoding txnip for treating a condition where improving the resistance towards oxidative stress has a beneficial effect, e.g., for improving female fertiliy or extending healthy lifespan.. .
Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechtes
A detergent composition comprising a subtilisin variant having the amino acid sequence set forth in seq id no: 1, and at least one additional ingredient selected from i) bleaches selected from percarbonates, persulphates and organic peracids, ii) aminocarboxylates, or iii) sulphonated polymers, or iv) organophosphoric acids or salts thereof and mixtures thereof is provided. Also provided is a detergent composition comprising a subtilisin variant having the amino acid sequence set forth in seq id no: 1, wherein the detergent composition is at least partially enveloped in a water soluble or water dispersible package.
Reckitt Benckiser N.v.
Method for producing rubber particles with reduced coagulation tendency, producing pneumatic tire, and producing rubber product
Provided is a method for producing rubber particles with a reduced coagulation tendency. The present invention relates to a method for producing rubber particles with a reduced coagulation tendency, the method including a step of performing protein synthesis in the presence of both rubber particles and a cell-free protein synthesis solution containing an mrna coding for a rubber elongation factor (ref) family protein to bind the ref family protein to the rubber particles..
Multi-specific binding proteins
This invention generally relates to multi-specific binding proteins. The invention also relates to methods of making such proteins and to methods of using such proteins.
Boehringer Ingelheim International Gmbh
Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.. .
St2 antigen binding proteins
Described herein are compositions and methods related to antigen binding proteins that bind to human st2, including antibodies. In particular embodiments, the disclosure provides fully human anti-st2 antibodies and deriviatives and variants thereof.
Human il-23 antigen binding proteins
Antigen binding proteins that bind to human il-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of il-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided..
Compositions and methods that involve protein scaffolds that specifically bind to hepatocyte growth factor receptor
This disclosure describes a non-naturally occurring protein scaffold that specifically binds to hepatocyte growth factor receptor (met) and methods of using such protein scaffolds. Generally, the protein scaffold includes a frame and at least one loop region that specifically binds hepatocyte growth factor receptor (met).
Regents Of The University Of Minnesota
Avian colony stimulating factor 1 receptor binding proteins
The present invention provides avian csf1 genes encoding proteins which bind avian colony stimulating factor 1 receptor (csf1r) and which exhibit immunomodulatory properties.. .
The University Court Of The University Of Edinburgh
Plant-derived elastin binding protein ligands and methods of using the same
The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of gxxpg (seq id no.
The Hospital For Sick Children